Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

British Journal of Haematology

Volumn 145, Issue 4, 2009, Pages 481-490

  Voorhees, Peter M ^a,b   Chen, Qing ^a   Small, George W ^a   Kuhn, Deborah J ^c   Hunsucker, Sally A ^c   Nemeth, Jeffrey A ^d   Orlowski, Robert Z ^c,e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill ^*

^d CENTOCOR INC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Akt; Bone marrow microenvironment; Glucocorticoid resistance; P44 42 mitogen activated protein kinase; Phosphatidylinositol 3 kinase

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CNTO 328; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANALYTIC METHOD; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DEATH; CYTOTOXICITY; DNA FRAGMENTATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL;

ANTIBODIES, MONOCLONAL; BORONIC ACIDS; CELL DEATH; CELL LINE, TUMOR; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE;

EID: 65349129390     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07647.x     Document Type: Article

References (54)

1. Alexanian, R., Dimopoulos, M.A., Delasalle, K. Barlogie, B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887 890.
2. Anderson, K.C., Jones, R.M., Morimoto, C., Leavitt, P. Barut, B.A. (1989) Response patterns of purified myeloma cells to haematopoietic growth factors. Blood, 73, 1915 1924. (Pubitemid 19145125)
3. Chatterjee, M., Honemann, D., Lentzsch, S., Bommert, K., Sers, C., Herrmann, P., Mathas, S., Dorken, B. Bargou, R.C. (2002) In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood, 100, 3311 3318. (Pubitemid 35217082)
4. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Treon, S., Urashima, M., Kharbanda, S. Anderson, K.C. (1997) Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 15, 837 843. (Pubitemid 27390136)
5. Chauhan, D., Hideshima, T., Pandey, P., Treon, S., Teoh, G., Raje, N., Rosen, S., Krett, N., Husson, H., Avraham, S., Kharbanda, S. Anderson, K.C. (1999) RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene, 18, 6733 6740.
6. Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F.E., Shima, Y., Tai, Y.T., Rosen, S., Avraham, S., Kharbanda, S. Anderson, K.C. (2000) SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. Journal of Biological Chemistry, 275, 27845 27850.
7. Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Catley, L., Tai, Y.T., Hayashi, T., Shringarpure, R., Burger, R., Munshi, N., Ohtake, Y., Saxena, S. Anderson, K.C. (2003) Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 102, 3379 3386. (Pubitemid 37314781)
8. Cheung, W.C. Van Ness, B. (2001) The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia, 15, 264 271. (Pubitemid 32175458)
9. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123 2132. (Pubitemid 350146107)
10. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467 1473. (Pubitemid 44264086)
11. Ferlin-Bezombes, M., Jourdan, M., Liautard, J., Brochier, J., Rossi, J.F. Klein, B. (1998) IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. Journal of Immunology, 161, 2692 2699. (Pubitemid 28425686)
12. + subpopulations that can proliferate in response to IL-6 in human myelomas. British Journal of Haematology, 105, 131 140. (Pubitemid 29197155)
13. Grigorieva, I., Thomas, X. Epstein, J. (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Experimental Haematology, 26, 597 603. (Pubitemid 28307527)
14. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H. Epstein, J. (1994) Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84, 3063 3070. (Pubitemid 24328099)
15. Harousseau, J.L., Attal, M., Leleu, X., Troncy, J., Pegourie, B., Stoppa, A.M., Hulin, C., Benboubker, L., Fuzibet, J.G., Renaud, M., Moreau, P. Avet-Loiseau, H. (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 91, 1498 1505.
16. Hideshima, T., Nakamura, N., Chauhan, D. Anderson, K.C. (2001a) Biologic sequelae of interleukin-6 induced PI3-K/Akt signalling in multiple myeloma. Oncogene, 20, 5991 6000. (Pubitemid 32955041)
17. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. Anderson, K.C. (2001b) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071 3076. (Pubitemid 32691956)
18. Honemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dorken, B. Bargou, R.C. (2001) The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. International Journal of Cancer, 93, 674 680. (Pubitemid 32695115)
19. Hsu, J.H., Shi, Y., Hu, L., Fisher, M., Franke, T.F. Lichtenstein, A. (2002) Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene, 21, 1391 1400. (Pubitemid 34214504)
20. Jagannath, S., Durie, B.G., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. Crowley, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776 783. (Pubitemid 40904528)
21. Jagannath, S., Richardson, P.G., Barlogie, B., Berenson, J.R., Singhal, S., Irwin, D., Srkalovic, G., Schenkein, D.P., Esseltine, D.L. Anderson, K.C. (2006) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica, 91, 929 934. (Pubitemid 44023146)
22. Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta, H. Herrlich, P. (1990) Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell, 62, 1189 1204. (Pubitemid 20333778)
23. Juge-Morineau, N., Francois, S., Puthier, D., Godard, A., Bataille, R. Amiot, M. (1995) The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. British Journal of Haematology, 90, 707 710.
24. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83 85. (Pubitemid 18083553)
25. Keats, J.J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.J., Van Wier, S., Tiedemann, R., Shi, C.X., Sebag, M., Braggio, E., Henry, T., Zhu, Y.X., Fogle, H., Price-Troska, T., Ahmann, G., Mancini, C., Brents, L.A., Kumar, S., Greipp, P., Dispenzieri, A., Bryant, B., Mulligan, G., Bruhn, L., Barrett, M., Valdez, R., Trent, J., Stewart, A.K., Carpten, J. Bergsagel, P.L. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 12, 131 144. (Pubitemid 47208626)
26. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517 526. (Pubitemid 19060538)
27. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R. Berenson, J. (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cellular Immunology, 162, 248 255.
28. Liu, P., Oken, M. Van Ness, B. (1999) Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia, 13, 473 480. (Pubitemid 29108087)
29. Mahmoud, M.S., Ishikawa, H., Fujii, R. Kawano, M.M. (1998) Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood, 92, 3887 3897. (Pubitemid 28525215)
30. Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J.F., Klein, B. Tarte, K. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 103, 3148 3157. (Pubitemid 38451693)
31. Ogawa, M., Nishiura, T., Oritani, K., Yoshida, H., Yoshimura, M., Okajima, Y., Ishikawa, J., Hashimoto, K., Matsumura, I., Tomiyama, Y. Matsuzawa, Y. (2000) Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Research, 60, 4262 4269. (Pubitemid 30636615)
32. Orlowski, R.Z., Small, G.W. Shi, Y.Y. (2002) Evidence that inhibition of p44/42 mitogen-activated protein kinase signalling is a factor in proteasome inhibitor-mediated apoptosis. Journal of Biological Chemistry, 277, 27864 27871.
33. Pene, F., Claessens, Y.E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C. Bouscary, D. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 21, 6587 6597. (Pubitemid 35177037)
34. Pollett, J.B., Trudel, S., Stern, D., Li, Z.H. Stewart, A.K. (2002) Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood, 100, 3819 3821. (Pubitemid 35303957)
35. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E. Gertz, M.A. (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, 4050 4053. (Pubitemid 41775908)
36. Rajkumar, S.V., Jacobus, S., Callander, N., Fonseca, R., Vesole, D., Williams, M.V., Abonour, R., Siegel, D.S., Katz, M. Greipp, P.R. (2008a) Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the eastern cooperative oncology group: analysis of response, survival, and outcome wi. Journal of Clinical Oncology (Meeting Abstracts), 26, 8504.
37. Rajkumar, S.V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. Blade, J. (2008b) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 2171 2177.
38. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 2498. (Pubitemid 41007864)
39. Rowley, M., Liu, P. Van Ness, B. (2000) Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood, 96, 3175 3180.
40. Salmon, S.E., Shadduck, R.K. Schilling, A. (1967) Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer chemotherapy reports. Part 1, 51, 179 187.
41. Schule, R., Rangarajan, P., Kliewer, S., Ransone, L.J., Bolado, J., Yang, N., Verma, I.M. Evans, R.M. (1990) Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell, 62, 1217 1226. (Pubitemid 20333780)
42. Tai, Y.T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.F., Rumizen, M., Burger, P., Morrison, A., Podar, K., Chauhan, D., Tassone, P., Richardson, P., Munshi, N.C., Ghobrial, I.M. Anderson, K.C. (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood, 110, 1656 1663. (Pubitemid 47443984)
43. Tassone, P., Neri, P., Burger, R., Savino, R., Shammas, M., Catley, L., Podar, K., Chauhan, D., Masciari, S., Gozzini, A., Tagliaferri, P., Venuta, S., Munshi, N.C. Anderson, K.C. (2005) Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clinical Cancer Research, 11, 4251 4258. (Pubitemid 40791592)
44. Touray, M., Ryan, F., Jaggi, R. Martin, F. (1991) Characterisation of functional inhibition of the glucocorticoid receptor by Fos/Jun. Oncogene, 6, 1227 1234.
45. + T cells. Journal of Clinical Investigation, 113, 619 627. (Pubitemid 38542511)
46. Tu, Y., Gardner, A. Lichtenstein, A. (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Research, 60, 6763 6770.
47. Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 3712 3720. (Pubitemid 24006055)
48. Voorhees, P.M., Chen, Q., Kuhn, D.J., Small, G.W., Hunsucker, S.A., Strader, J.S., Corringham, R.E., Zaki, M.H., Nemeth, J.A. Orlowski, R.Z. (2007) Inhibition of interleukin-6 signalling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clinical Cancer Research, 13, 6469 6478. (Pubitemid 350075037)
49. Voorhees, P.M., Manges, R.F., Sonneveld, P., Somlo, G., Jagannath, S., Zweegman, S., Munteanu, M., Vermeulen, J.T., Xie, H. Orlowski, R.Z. (2008) Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology (Meeting Abstracts), 26, 8593.
50. Wang, W., Hayashi, J. Serrero, G. (2006) PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma. Clinical Cancer Research, 12, 49 56. (Pubitemid 43166175)
51. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 2142. (Pubitemid 350146108)
52. Xu, F., Gardner, A., Tu, Y., Michl, P., Prager, D. Lichtenstein, A. (1997) Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. British Journal of Haematology, 97, 429 440. (Pubitemid 27224626)
53. Xu, F.H., Sharma, S., Gardner, A., Tu, Y., Raitano, A., Sawyers, C. Lichtenstein, A. (1998) Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood, 92, 241 251. (Pubitemid 28303199)
54. Yang-Yen, H.F., Chambard, J.C., Sun, Y.L., Smeal, T., Schmidt, T.J., Drouin, J. Karin, M. (1990) Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell, 62, 1205 1215. (Pubitemid 20333779)